EGFR Positive Non-small Cell Lung Cancer
Showing NaN - NaN of 2
NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV Trial in Worldwide (Dacomitinib)
Active, not recruiting
- NSCLC Stage IIIB
- +4 more
-
Hong Kong, Hong Kong
- +8 more
Jan 10, 2023
Osimertinib for Advanced EGFR-positive NSCLC Patients
Recruiting
- EGFR Positive Non-small Cell Lung Cancer
- Non Small Cell Lung Cancer
-
Singapore, SingaporeNational University Hospital
Aug 31, 2021